Sort   by:  
 Page size 
UnknownApolipoprotein E genotype and outcome in infants with hypoxic-ischemic encephalopathy.
Not available
S-EPMC4095992 | biostudies-literature
UnknownPharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Not available
S-EPMC9070820 | biostudies-literature
UnknownNovel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
Not available
S-EPMC4432148 | biostudies-literature
UnknownClinical and diagnostic features of central nervous system tuberculosis in Indian children - a descriptive study.
Not available
S-EPMC11406600 | biostudies-literature
UnknownPyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.
Not available
S-EPMC11622436 | biostudies-literature
UnknownEthambutol Population Pharmacokinetics and Pharmacodynamics From a Phase 3 Confirmatory Trial for the Treatment of Tuberculosis.
Not available
S-EPMC13629508 | biostudies-literature
UnknownEfavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Not available
S-EPMC9890454 | biostudies-literature
UnknownRifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Not available
S-EPMC10169427 | biostudies-literature
UnknownHigh-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Not available
S-EPMC7307310 | biostudies-literature
UnknownPharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.
Not available
S-EPMC7662174 | biostudies-literature
Sort   by:  
 Page size